Scroll for more
Scroll for more
When RNAi therapeutics silence the genes that cause disease, the best parts of life can be amplified
Scroll to see more
Living with disease is noisy. The day-to-day of life is filled with unpleasant and unwanted sounds, both heard and felt. The noises of a busy doctor's office. The rattle of pills. The expressions of regret for activities and experiences declined because you don't feel well or are physically limited.
Over time, these sounds mute the joy of life.
RNA interference (RNAi) is a natural process that’s already at work inside your cells controlling which genes are active, and in doing so, which how many proteins they make. Proteins are responsible for many of your body’s functions, but they can also cause or contribute to disease. The discovery of RNAi was awarded the Nobel Prize in 2006.
RNAi therapeutics are medicines that utilize the RNA interference process to treat disease. RNAi therapeutics were invented by Alnylam.
RNAi therapeutics target and disrupt the production of proteins known to either cause or contribute to disease. Scientists create specific RNAi therapeutics to treat specific diseases. By disrupting the production of a given protein, that gene is effectively “silenced.”
While it sounds rather simple, using RNAi to treat disease is a
revolutionary approach.
While it sounds rather simple, using RNAi to treat disease is a
revolutionary approach.
Where most other types of medicines target proteins that cause or contribute to disease after they're made, RNAi therapeutics prevent those proteins from being made in the first place.
This approach is unlocking new possibilities for treating diseases and reducing the frequency with which medicines need to be taken.
See our pipeline ›As cutting-edge as this sounds, research into the safety and effectiveness of RNAi therapeutics is extensive and is based on over a decade of clinical trials.
The world’s first RNAi therapeutic, and Alnylam’s first commercial medicine, was approved in 2018. Since then, five other therapies have been approved in the United States and around the world.
Alnylam was founded in 2002 to translate the discovery of RNA interference into a new class of medicines. Through dedicated research and development over more than 20 years, we have delivered the breakthroughs and innovations that have made RNAi therapeutics possible. Now, we're leading what's next, working to apply this approach to new diseases and new tissues.
We’re pushing the science of RNAi forward because...
We believe that all patients, regardless of their
diagnosis, have the potential to benefit from the promise that RNA interference holds...
to Silence their Disease,.
so they can Amplify Life.
to Silence their Disease,.
so they can Amplify Life.
